Chapter 81: Drugs for Allergic Rhinitis, Cough, and Colds

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when you think about the human immune system, you picture this incredibly disciplined, highly trained army.

Right, a very coordinated biological defense mechanism.

Yeah, exactly.

It recognizes a threat, neutralizes it, and restores order.

It's precision at its finest, but then you look at allergic rhinitis and suddenly that disciplined army looks a lot less like a military operation and, well, a lot more like a five -year -old's birthday party after way too much cake.

That is a remarkably accurate,

if slightly chaotic, way to describe the pathophysiology here.

Welcome to our deep dive.

Today, we are talking directly to you.

Maybe you're a nursing student gearing up for a major pharmacology exam or, you know, maybe stepping onto the floor for your first clinical rotation.

And this is such a vital area of practice for you to master.

It really is.

Our mission today is to completely conquer Chapter 81 of Lenz Pharmacology for Nursing Care.

We are mastering the pharmacology of allergic rhinitis, coughs, and colds.

Right, we're taking all that dense drug information, the safety alerts, the specific nursing implications, and translating it into, like, clear, actionable clinical knowledge.

Because these are largely outpatient, over -the -counter conditions, right?

So nurses are heavily relied upon to provide accurate patient education and catch dangerous interactions before they even happen.

Oh, absolutely.

You are the front line for this stuff.

So let's go back to that birthday party analogy.

The text defines allergic rhinitis by its major symptoms, which are sneezing, rhinorrhea, keratitis, and nasal congestion.

Right, the classic runny, itchy, stuffy nose.

Yeah.

But to actually understand the drugs, we have to understand the biological why first.

We need to look at the mast cells.

Yes.

The pathophysiology is always the absolute foundation of the pharmacology.

So with allergic rhinitis, airborne allergens think pollen, pet dander, dust mites.

They enter the upper airway.

And they find those mast cells.

Exactly.

These allergens bind to immunoglobulin E, or IgE, antibodies, which are, you know, permanently attached to the surface of mast cells right there in the nasal mucosa.

So think of the mast cell as a piñata.

The allergen is the stick hitting it.

And when that stick hits the IgE antibodies, the piñata breaks open.

I love that visual.

Right.

And all the inflammatory mediators spill out.

But instead of candy, it's histamine, leukotrienes, and prostaglandins, causing absolute chaos in the airway.

And that chaos is very specific mechanically.

Histamine and leukotrienes cause profound basal dilation and increased capillary permeability.

Meaning the blood vessels in the nose literally swell up and leak fluid into the surrounding tissue.

Yes, exactly.

That is what causes the rhinorrhea and the severe nasal congestion.

And the text notes this affects almost one out of every six people in the U .S.

Wow.

One in six.

So you are going to see this constantly in practice.

Constantly.

So if the piñata spilling is the core problem, I'm guessing the absolute best pharmacological approach is to just prevent it from breaking in the first place.

You would be correct.

Which brings us to the intranasal glucocorticoids.

The heavy hitters.

The text flat out says these are the most effective drugs for both prevention and treatment.

They really are the undisputed champions because they suppress the entire inflammatory cascade.

Glucocorticoids essentially take the stick away and reinforce the piñata.

So they don't just block one thing.

Right.

Because they have broad anti -inflammatory actions, they don't just block histamine.

They actually prevent the synthesis and release of leukotrienes and prostaglandins too.

That's amazing.

So that means they suppress all the major symptoms simultaneously, right?

Congestion, rhinorrhea, sneezing, and nasal itching.

All of it.

But when you look at the different options the text compares,

there's a massive nursing implication regarding which specific spray a provider might order.

Yeah, I noticed that.

In table 81 .2, it highlights drugs like sickle cyanide, fluticazone, and memetazone for having incredibly low bioavailability.

Right.

But, I mean, if I'm spraying something directly into a patient's nose, why do I care about bioavailability?

That is a brilliant clinical thinking connection to make.

So bioavailability refers to how much of the active drug enters the systemic blood circulation.

We want these glucocorticoids to stay completely local, right there in the nasal mucosa.

But when a patient uses a nasal spray, some of it inevitably drips down the back of the throat.

Yeah, that awful post -nasal drip taste.

Exactly.

So they swallow it, and it gets into the GI tract.

If a glucocorticoid has high bioavailability, it gets absorbed systemically, and you run the risk of systemic steroid side effects.

Which we know from earlier chapters can be devastating.

I mean, immunosuppression, osteoporosis, hyperglycemia.

Right.

By using second -generation agents with very low bioavailability like fluticazone, even if the patient swallows some of the dose, it undergoes massive first -pass metabolism in the liver.

So it basically gets destroyed before it can do any harm.

Exactly.

It never reaches the systemic circulation in meaningful amounts.

That makes perfect sense.

The text points out the adverse effects are mostly mild and local, like nasal drying, maybe a burning sensation, or epistaxis nosebleeds.

Yeah, usually very tolerable.

But it does highlight a rare, yet crucial, pediatric monitoring parameter that we need to talk about.

Yes, this is huge for your exams.

Systemic absorption, even in small amounts over a long period, can cause adrenal suppression and, specifically in pediatric patients, a potential slowing of linear bone growth.

Wow.

So it can literally stunt their growth.

Potentially, yes.

That is exactly why those low bioavailability agents are the gold standard for kids.

And as a nurse doing patient education, you must teach that these sprays have to be dosed daily, not PRN or just when they feel like it.

Correct.

For seasonal allergies, it can take a week or more to see the maximal effect, and up to two to three weeks for perennial indoor allergies.

So they aren't a quick fix.

They are a long -term stabilization strategy.

But let's say the patient didn't use a prophylactic spray.

The pinata has broken.

The airway is flooded with histamine.

Now we need the other heavy hitters, the antihistamines, specifically H1 receptor antagonists.

Right, the rescue meds, essentially.

But there is a huge clinical distinction here that surprised me.

Antihistamines relieve sneezing, runny nose, and itching.

But they do absolutely nothing for congestion.

Why is that?

Because histamine doesn't actually cause the congestion.

Wait, really?

Yeah.

Histamine triggers the itching and the sneezing reflexes, and it increases capillary permeability, which causes the runny nose.

But the actual engorgement of the nasal blood vessels, like the swelling that blocks the airway, that is primarily driven by other mediators, like leukotrienes.

So blocking histamine stops the itch and the drip, but it doesn't shrink the swollen tissue.

The text compares first and second generation antihistamines in table 81 .3, and the differences are basically night and day.

Very different profiles.

You have first generation drugs like diphenhydramine versus second generation like fixofenadine and loratadine, assuming the primary difference comes down to the blood -brain barrier.

You hit the nail on the head.

First generation agents are highly lipid soluble, so they cross the blood -brain barrier with ease.

Which means they get right into the breath.

Exactly.

Once in the central nervous system, they block H1 receptors there, which causes significant, sometimes completely debilitating sedation.

So you're asleep, basically.

Right.

But second generation agents are large, less lipid soluble molecules.

They do not readily cross the blood -brain barrier, making them non -sedating.

Which makes them the clear choice for, say, a college student cramming for an exam or anyone operating heavy machinery.

Oh, absolutely.

But first generation drugs also carry strong anticholinergic effects, right?

Yes, they do.

They don't just block histamine, they also block muscarinic receptors.

That causes the classic anticholinergic side effects, dry mouth, constipation, and urinary hesitancy.

The text also mentions two intranasal antihistamines, azelestine and olipatidine.

Interestingly, even though they are local sprays, they can still cause somnolence, plus this bitter taste that patients tend to hate.

Yeah, compliance can be tricky with those.

But let me challenge a clinical assumption here.

If first generation antihistamines are so good at drying out secretions due to those anticholinergic effects, why shouldn't my patient just take deconhydramine for a common infectious cold?

I mean, if my nose is running like a leaky faucet, I want to dry it out.

Right, it seems entirely logical.

But it's actually a massive clinical trap.

This is a crucial cause and effect you really need to understand for your exams and your practice.

Okay, I'm listening.

Histamine does not contribute to the symptoms of an infectious viral cold.

Wow, so it's just the wrong mechanism entirely.

Completely wrong.

Using an antihistamine for a cold doesn't treat the root inflammatory cause of the virus.

And worse, those anticholinergic effects dry out the respiratory secretions.

So that thickens them up.

Exactly.

They take normal, thin, runny mucus and turn it into a thick, viscous sludge that is incredibly hard for the patient to cough up or expel.

And when thick, stagnant mucus just sits there in the warm, dark airway.

It creates a perfect warm, moist environment for secondary bacterial proliferation.

You can easily turn a simple viral cold into a stubborn bacterial sinus infection just by misusing an antihistamine.

That is a phenomenal connection to make.

So if antihistamines leave us completely stuffed up with congestion, how do we actually shrink those swollen blood vessels?

We have to turn to the sympathomimetics or decongestants, like phenylephrine and pseudoephedrine.

If the issue is swollen, leaky blood vessels.

I'm assuming we need to trigger the sympathetic nervous system to clamp them down.

Is that where alpha -1 receptors come in?

Precisely.

Sympathomimetics activate alpha -1 adrenergic receptors located directly on the nasal blood vessels.

Fight or flight response.

Yes.

Remember from your autonomic nervous system review, alpha -1 activation causes vasoconstriction.

When those nasal blood vessels clamp down, the swollen nasal membranes shrink, the airway opens up, and drainage can finally occur.

So we have two main routes for these.

Topically, like as drops and sprays, or orally as a pill,

topical decongestants are incredibly fast and intense.

But the text flags a massive safety alert here, which is rebound congestion.

Rebound congestion, or rhinitis medicamentosa, is a notorious adverse effect of topical decongestants.

If a patient uses a Nengel spray for more than three to five days, a vicious physiological cycle begins.

Like an addiction to the spray.

Basically.

As the drug wears off, the congestion comes back even worse than before.

The receptors essentially down -regulate, demanding more of the drug to achieve the exact same vasoconstriction.

So the patient ends up using more spray more frequently.

Right.

Leading to escalating congestion and total dependency.

So as the nurse, when a patient comes to you completely dependent on their nasal spray, how do you advise them to break that cycle?

Well, abrupt withdrawal is incredibly uncomfortable.

So the text recommends two main strategies.

Okay, what's the first one?

One, discontinue the drug in one nostril at a time.

It's annoying, but it ensures they can still breathe through at least one side while the other side recovers.

That's smart.

Two, an even better option is to start an intranasal glucocorticoid in both nostrils for two to six weeks, beginning one week before stopping the decongestant.

The steroid suppresses the baseline inflammation and sort of cushions the blow of the withdrawal.

And as a quick nursing implication, if a provider orders topical decongestants for young children, drops are always preferred over sprays, right?

Absolutely.

A nurse can control the exact number of drops administered, whereas a spray delivers a variable dose that can easily lead to pediatric toxicity.

That is a great clinical tip.

Now, what about the oral route?

They take longer to work.

In the text notes, there's no rebound congestion, which is a huge plus.

But because you are swallowing a pill, the drug goes everywhere.

Exactly.

You get systemic vasoconstriction.

Which is fine for me, but maybe not my grandparents.

Right.

For a healthy 20 -year -old, that might not be a big deal.

But for a patient with hypertension,

coronary artery disease, or cardiac arrhythmias,

widespread vasoconstriction is a serious cardiovascular hazard.

It forces the heart to pump against a much higher afterload.

Yes.

Oral decongestants also penetrate the central nervous system, causing excitation like restlessness, anxiety, and insomnia.

Which perfectly sets up this fascinating real -world context the text dives into regarding the Combat Methamphetamine Epidemic Act of 2005.

Oh yeah, the pseudoephedrine restriction.

Pseudoephedrine is an incredibly effective oral decongestant.

But if you walk into a pharmacy today, you can't just grab it off the shelf.

Right.

Because pseudoephedrine causes CNS stimulation similar to amphetamines, and it can easily be chemically converted into methamphetamine.

So by federal law, it's locked behind the pharmacy counter.

You have to show a government -issued ID, sign a log, and adhere to strict daily and monthly purchasing limits.

It's highly regulated now.

So because of those restrictions, the pharmaceutical industry heavily markets oral phenylephrine, which is sitting right out there in the open aisle.

But the text essentially says oral phenylephrine is practically useless.

Why are patients buying a drug that doesn't work?

Because of massive first -pass metabolism.

When you swallow phenylephrine, it goes through the GI tract straight to the liver.

And the liver just destroys it?

Pretty much.

The liver enzymes essentially metabolize and destroy the vast majority of the drug before it ever reaches systemic circulation.

Clinical trials show its efficacy is barely better than a placebo.

Wow.

So when your patient complains that their over -the -counter cold meds aren't working,

you now know the exact pharmacokinetic reason why.

Yep.

It never even makes it to the nose.

But since no single drug is perfect, and patients with cardiac issues obviously can't take systemic decongestants,

the text walks through a few alternative therapies for rhinitis.

Let's start with intranasal cromalin sodium.

So cromalin is incredibly safe, but it's really only moderately effective.

It works by stabilizing the membrane of the mast cell, preventing the release of those inflammatory mediators.

But unlike glucocorticoids, which actively suppress the inflammatory response, cromalin is just a preventative stabilizer.

Right.

The key nursing teaching point here is timing.

It takes one to two weeks to work, so it must be taken prophylactically before allergen exposure even begins.

So we have aprotropium.

This is an anti -cholinergic agent.

I like to think of this one as literally turning off the leaky faucet.

That's the perfect visualization.

It blocks cholinergic receptors, which directly inhibit secretions from the serous and ucus glands in the nasal mucosa, effectively stopping rhinorrhea.

But it does absolutely nothing for congestion or sneezing, right?

Correct.

The massive clinical benefit here, though, is safety.

Because it's a quaternary ammonium compound, it carries a positive charge and doesn't readily cross -cell membranes.

So you don't get the systemic anti -cholinergic side effects, like dry mouth or urinary retention.

You just get local nasal drying.

Exactly.

Now, let's talk about a drug that carries a critical safety alert.

Montelucast.

It's a leukotrine receptor antagonist.

We established earlier that leukotrienes drive nasal congestion, so blocking them is great.

But there is a major nursing monitoring parameter.

Yes.

And this is a classic board exam topic.

Montelucast carries a very real risk for rare but severe neuropsychiatric effects.

That's scary.

Like what?

We are talking about agitation, hallucinations, severe depression, and suicidal thinking and behavior.

Wow.

Because of this profound risk, the text is explicit.

Montelucast should generally be reserved for patients who have failed or cannot tolerate intranasal glucocorticoids or antihistamines.

You definitely cannot just hand that out without severe caution and thorough patient education regarding mood changes.

Absolutely not.

The text also briefly notes monoclonal antibodies, like omelizumab and duplumab.

They are used completely off -label for severe, stubborn cases of allergic rhinitis when nothing else works, though they are primarily asthma drugs.

Right.

They target the IgE antibodies directly.

But given their cost and administration route,

their injections are absolute last line therapies.

Let's pivot slightly.

All this post -nasal drip and upper airway irritation usually leads to one highly annoying symptom.

A cough.

The worst.

The text dedicates an entire section to antitussives.

But it asks a fundamental physiological question first.

When is a cough actually a good thing?

Because we don't always want to suppress it, right?

Coughing is a complex vital reflex that removes foreign matter and excess respiratory secretions.

If a patient has chronic lung disease like emphysema or asthma, and they have a productive cough, you absolutely do not want to suppress it.

They need to clear those lungs to prevent pneumonia.

Right.

We only target coughs that are nonproductive, painful, or completely depriving the patient of sleep.

To suppress those specific nonproductive coughs, we turn to antitussives.

Starting with the opioid antitussives, specifically codeine, which the text calls the most effective cough suppressant available.

Now, when the general public hears opioid, they immediately think of high addiction potential and severe respiratory depression.

How do we reconcile that with cough syrup?

Well, it all comes down to the dosage.

Codeine suppresses the cough reflex by acting directly on the medullary cough center in the brainstem.

Okay.

To achieve this, codeine is used at about one -tenth of the dose required to produce pain relief.

At that incredibly low dose, the risk for physical dependence or euphoria is actually quite small.

Oh, that makes sense.

In fact, codeine cough mixtures are Schedule V, which is the lowest restriction schedule for controlled substances.

But the nursing implications are still present, even at low doses.

You must monitor for respiratory depression,

exercise extreme caution in patients with reduced respiratory reserve,

and always, always know where the naloxone is, just in case of an overdose or unexpected sensitivity.

Good nursing practice, always.

What about the non -opioid options?

Dextramethorphan is the most common over -the -counter choice.

Dextramethorphan is fascinating.

It is technically an opioid derivative, but it doesn't activate opioid receptors, so it doesn't produce typical euphoria or physical dependence at therapeutic doses.

And it also works on the brainstem.

Yes.

However, the text warns that at very high doses, it blocks NMDA receptors in the brain.

This causes a state of mind -body dissociation that is clinically and pharmacologically similar to PCP.

That's terrifying for a drug you can buy at a grocery store.

It really is, and it has significant abuse potential, particularly among adolescents.

But maybe not as clinically terrifying as this next non -opioid.

Benzanatate, brand name Tessalon.

This drug has a completely different mechanism.

It's a structural analog of local anesthetics, like Procaine, and it works by decreasing the sensitivity of the stress receptors in the respiratory tract.

Right.

It numbs them.

But there is a massive safety alert here that every single nurse needs to memorize.

Absolutely.

Because it is a local anesthetic analog, benzanatate comes in capsule form, and those capsules must be swallowed intact.

Never.

If a patient sucks or chews on them, the drug acts as a local anesthetic right there in the mouth, pharynx and larynx.

It literally numbs the airway.

Which abolishes the gag reflex.

Yes.

And it can cause immediate life -threatening laryngospasm, bronchospasm, and total circulatory collapse.

The text explicitly notes that accidental ingestion of just one or two of these capsules has been fatal in toddlers.

You have to educate your patients on exactly how to swallow this drug safely and how to store it under lock and key away from kids.

Patient education here isn't just a suggestion.

It literally saves lives.

Let's round out the cough section with the difference between expectorants and mucolytics.

Clinically, how do you keep these mechanisms straight?

So an expectorant, like guifinesin, which most people know as mucinex, stimulates the flow of respiratory tract secretions.

So it makes it more watery.

Basically, it essentially adds water to the mucus, making the cough more productive.

Though the text notes you often need very high doses for it to actually work effectively.

A mucolytic, on the other hand, is much more direct.

It breaks down the mucus itself, right?

Yes.

It chemically reacts with the mucus molecules to break their disulfide bonds, making the mucus significantly less viscous.

What's the main drug for that?

The main mucolytic the text mentions is inhaled acetylcysteine.

And there are two big nursing warnings here.

One, it can trigger bronchospasm, so it shouldn't be given to asthmatics without caution.

And two, well, the smell.

Oh yes, it has a high sulfur content, so it smells distinctly like rotten eggs.

You definitely want to warn your patient before you strap a nebulizer mask to their face that smells like a stagnant swamp.

Here, breathe this in deeply, ignore the stench.

Good luck with that.

It definitely requires some therapeutic communication.

As we near the end of our chapter, we are entering the pediatric danger zone as we discuss cold remedies.

Let's do a quick clinical reality check on the common cold.

It's an acute viral infection, right?

There is no cure.

The text explicitly states there is no solid clinical proof that mega doses of vitamin C or zinc actually prevent or cure the cold.

And routine antibiotics are completely useless and actually harmful due to resistance unless a secondary bacterial infection develops.

Because there's no cure, treatment is purely symptomatic.

And the pharmaceutical industry has responded by flooding the market with thousands of combination cold remedies.

Which sounds convenient, but… Right, the text outlines several major clinical pitfalls with combination drugs.

First, the fixed dosages.

One combination pill might give you a therapeutic dose of a decongestant, but a completely subtherapeutic dose of an antitussive or vice versa.

Plus you end up taking drugs you don't even need.

If a patient just has a runny nose, why are they taking a capsule that also contains a heavy cough suppressant and acetaminophen?

It just exposes them to unnecessary drug toxicity.

Exactly.

And perhaps the most frustrating issue for healthcare providers doing medication reconciliation.

FDA rules allow manufacturers to secretly reformulate the active ingredients under the exact same brand name.

Wait, really?

Yes.

You have no guarantee that the cold and flu medicine the patient bought today has the same active ingredients as the one they bought last year unless you explicitly read the fine print on the back of the box.

Which brings us to the climax of this deep dive.

The pediatric safety alert regarding cold remedies.

The text cites stark warnings from both the CDC and the American Academy of Pediatrics.

This is a harsh clinical reality that nurses must advocate for.

Over the counter, cold remedies should not be used in young children.

Period.

The American Academy of Pediatrics says absolutely avoid them under six years of age.

Manufacturers voluntarily revise labels to say under four.

Because kids aren't just tiny adults.

The physiological bottom line is this.

Their central nervous systems are more permeable and their liver enzymes metabolize drugs differently.

There is zero clinical proof of efficacy in pediatric patients but absolute proof of serious life -threatening harm.

The text mentions thousands of emergency department visits for convulsions, severe tachycardia, hallucinations, and devastatingly infant deaths.

Often from accidental overdoses of combination drugs containing pseudoephedrine and first -generation antihistamines.

Because of that severe risk, your patient teaching as a nurse is critical.

Parents must be explicitly taught to never ever use adult medications for children.

And dosing is so important.

They must use the specific measuring syringe or cup provided with the pediatric product.

Never a household kitchen spoon, which varies wildly in volume.

And most importantly, they must be warned to never use antihistamine containing products merely to sedate a child so they will sleep.

That is such a heavy but absolutely vital responsibility for the nurse.

We spend so much time in nursing school studying the heavy prescription drugs, right?

The complex cardiac drips, the broad spectrum IV antibiotics, the chemotherapies.

It is so easy to dismiss Chapter 81 as just the over -the -counter aisle.

But look at the mechanisms we've uncovered.

The systemic cardiovascular risks of oral decongestance for a hypertension patient.

The severe neuropsychiatric risks of Montelucast.

The fatal layering bosbasm risk if a toddler chews a benzinotate capsule.

Exactly.

The public views these medications as inherently safe simply because they don't require a doctor's signature.

But they are powerful pharmacological agents.

And when the system assumes they are safe,

the nurse becomes the absolute critical last line of defense.

You are the one who checks the blood pressure before they take the pseudoephedrine.

You are the one who educates the mom to put down the adult cough syrup.

But, you know, it leaves me thinking about the future of how we handle this aisle.

We treat OTC meds as a massive trial and error experiment.

A patient tries five different cough syrups until one works.

But what if we didn't have to guess?

Oh, you're talking about pharmacogenomics.

Exactly.

Imagine a future where instead of blindly trusting a combination cold remedy, a quick genetic swab tells us exactly how a patient's liver enzymes are going to metabolize dextromethorphin or codeine.

That would be incredible.

We would know immediately if they're an ultra -rapid metabolizer who might suffer a toxic overdose from a standard dose or a poor metabolizer who will get zero relief.

We could completely eliminate the guesswork and the adverse pediatric reactions by tailoring even the most common cold medicines to the individual's DNA.

It would completely revolutionize the over -the -counter aisle.

Until then, though, knowledge of these physiological mechanisms is what allows you to intercept those clinical errors before they happen.

So as you head into your pharmacology exams or your next clinical shift, remember the invisible power of the over -the -counter aisle.

Trust your knowledge, advocate for your patients, and you're going to crush it.

A warm thank you from the Last Minute Lecture team for joining us today.

Keep asking why, keep connecting to the Dots, and we'll catch you on the next Deep Dive.